<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>PERRIGO SEB PREV- sulfacetamide sodium cream </strong><br>Perrigo New York Inc<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>SEB-PREV™ CREAM (SODIUM SULFACETAMIDE 10%)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e2811a9-5b3b-4e47-af4d-d693655233ef"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">Seb-Prev Cream</span></span></p>
<p><span class="Bold"><span class="Italics">(Sodium Sulfacetamide 10%)</span></span></p>
<p><span class="Bold"><span class="Italics">Rx Only</span></span></p>
<p><span class="Bold">FOR DERMATOLOGIC USE ONLY</span></p>
<p><span class="Bold">NOT FOR OPHTHALMIC USE</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bc4091f4-8d67-4b2d-be3a-fe62fbf27853"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each gram of Seb-Prev™ Cream contains 100 mg of Sulfacetamide Sodium USP in a vehicle consisting of benzyl alcohol, cetyl alcohol, dimethicone, edetate disodium, emulsifying wax, glycerin, isopropyl myristate, monobasic sodium phosphate, PEG-8 stearate, propylene glycol monopalmitostearate, purified water and sodium thiosulfate. </p>
<p>Sulfacetamide sodium is C8H9N2NaO3S•H2O with a molecular weight of 254.24. Chemically, it is Acetamide <span class="Italics">N</span>-[(4-aminophenyl)sulfonyl]-, monosodium salt, monohydrate, with the following structural formula:</p>
<div class="Figure">
<img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=51e81749-8306-4e3e-9165-28c34cdcca62&amp;name=746e4edd-4c3e-443a-9775-d64d494f1850-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Sulfacetamide sodium is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform, and in ether.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_66330f61-3ff0-4dc2-b211-f175e9d58c1d"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Sulfacetamide sodium exerts a bacteriostatic effect against sulfonamide sensitive Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with <span class="Italics">para</span>-aminobenzoic acid. There are no clinical data available on the degree and rate of systemic absorption of Seb-Prev™ Cream when applied to the skin or scalp. However, significant absorption of sulfacetamide sodium through the skin has been reported.</p>
<p>The following <span class="Italics">in vitro </span>data are available but their clinical significance is unknown. Organisms which show susceptibility to sulfacetamide sodium are: <span class="Italics">Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>species, <span class="Italics">Proteus vulgaris, Nocardia </span>and <span class="Italics">Actinomyces.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_d890ac84-1989-4b0c-a628-0bee4dbd6160"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Seb-Prev™ Cream is intended for topical application in the following scaling dermatoses: <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span> and <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span> sicca (<span class="product-label-link" type="condition" conceptid="4308080" conceptname="Pityriasis simplex">dandruff</span>). It also is indicated for the treatment of secondary <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of the skin due to organisms susceptible to sulfonamides.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_5593ed32-ddbc-44dc-a664-9b9afdbe8438"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Seb-Prev™ Cream is contraindicated in persons with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulfonamides or to any of the ingredients of the product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_31d3e4cd-8d1c-45ec-95c7-36888af7652f"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Sulfonamides are known to cause <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> in hypersensitive individuals. <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> also has been reported following the use of sulfacetamide sodium topically. Cases of drug-induced <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d0a9c8e5-2437-4dad-8518-79e7746a4bfb"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_834ca83c-5ed8-4e30-86a3-af66ec0039e0"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may recur when a sulfonamide is readministered, irrespective of the route of administration, and cross <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> between different sulfonamides may occur. If Seb-Prev™ Cream produces signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or other untoward reactions, discontinue use of the preparation. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded, or severely burned areas. Under these circumstances, potentially any of the adverse effects produced by the systemic administration of these agents could occur and appropriate observations and laboratory determinations should be performed.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_9613b73f-dccb-4694-a686-59b237c60485"></a><a name="section-7.2"></a><p></p>
<h2>Information For Patients</h2>
<p class="First">Patients should discontinue Seb-Prev™ Cream if the condition becomes worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> develops in the area being treated or elsewhere. Seb-Prev™ Cream also should be discontinued promptly and the physician notified if any <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or sores in the mouth develop. </p>
<p>For external use only. Avoid contact with eyes and mucous membranes.</p>
<p>Keep this and all medications out of reach of children. In case of accidental ingestion, call a physician or poison control center immediately (see<a href="#i4i_overdosage_id_dd159d9a-c9f9-405e-a2e1-3740965b4ac1">OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_cf572536-ce44-497f-9f2e-8c5cadb706f1"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Seb-Prev™ Cream is incompatible with silver preparations.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_921fb195-1982-417b-934f-fa2370b9b531"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Long-term animal studies for carcinogenic potential have not been performed on Seb-Prev™ Cream to date. Studies on reproduction and fertility also have not been performed. One author detected chromosomal nondisjunction in the yeast, <span class="Italics">Saccharomyces cerevisiae, </span>following application of sulfacetamide sodium. The significance of this finding to the topical use of sulfacetamide sodium in the human is unknown.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_cd223e1a-ec04-4832-be51-cf09a544389e"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_14f16d1c-4399-4a22-90e4-0f2a5ef2a472"></a><a name="section-7.5.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_C_id_74217861-0713-46eb-a57d-3c1a68a4e665"></a><a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproduction studies have not been conducted with Seb-Prev™ Cream. It also is not known whether Seb-Prev™ Cream can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Seb-Prev™ Cream should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_39558d80-0b16-49a6-b8df-7d437ff0845f"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Seb-Prev™ Cream is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_933a5c84-7fb4-4737-b6e4-ee90bcd2f2c4"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children under the age of 12 years have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_646899e4-ebec-42f8-a30b-64cca2f46479"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Reports of irritation and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulfacetamide sodium are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sulfacetamide sodium, are noteworthy: instances of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and instances of local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> which progressed to a syndrome resembling <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>; in one case a fatal outcome has been reported (see <a href="#i4i_warnings_id_31d3e4cd-8d1c-45ec-95c7-36888af7652f">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_dd159d9a-c9f9-405e-a2e1-3740965b4ac1"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The oral LD50 of sulfacetamide in mice is 16.5 g/kg. The LD50 for topical administration of sulfacetamide has not been determined. Oral overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Large oral overdosage may cause <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. In the event of overdosage, call a physician or poison control center; emergency treatment should be started immediately. </p>
<p>Treatment: The patient should be induced to vomit, even if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> has occurred spontaneously. Pharmacologic <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by the administration of ipecac syrup is a preferred method. However, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> should not be induced in patients with impaired consciousness. The action of ipecac is facilitated by physical activity and by the administration of eight to twelve fluid ounces of water. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> does not occur within 15 minutes, the dose of ipecac should be repeated. Precautions against <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> must be taken, especially in infants and children. Following <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, any drug remaining in the stomach may be absorbed by activated charcoal administered as a slurry with water. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is unsuccessful or contraindicated, gastric lavage should be performed. Isotonic and one-half isotonic saline are the lavage solutions of choice. Saline cathartics, such as milk of magnesia, draw water into the bowel by osmosis and, therefore, may be valuable for their action in rapid dilution of bowel content. After emergency treatment, the patient should continue to be medically monitored. </p>
<p>Observe kidney function for up to 1 week and have the patient ingest copious amounts of fluid during this period. Mannitol infusions may be helpful at the first sign of <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>. Alkalinization of the urine by ingestion of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is very helpful in preventing crystallization of sulfa drug in the kidney.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8ff4f3eb-d932-4dc6-8542-9e61d92dac4c"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">Seborrheic dermatitis</span> including <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span> sicca: </span>Apply to affected areas twice daily (morning and evening), or as directed by your physician. Avoid contact with eyes or mucous membranes. Repeat application as described for eight to ten days. As the condition subsides, the interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of Seb-Prev™ Cream should be reinitiated as at the beginning of treatment.</p>
<p><span class="Bold">Secondary cutaneous <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>: </span>Apply to affected areas twice daily for eight to ten days.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d0fef931-1542-413e-8a9b-2ef8d8e79d60"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Seb-Prev™ Cream is available as follows:</p>
<p>30 g tube (NDC 45802-<span class="Bold">954</span>-94)</p>
<p>60 g tube (NDC 45802-<span class="Bold">954</span>-96)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_4165dee8-2801-40a2-9d3f-7687fd674ce8"></a><a name="section-12"></a><p></p>
<p class="First">Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Do not freeze. </p>
<p>Occasionally, a slight yellowish discoloration may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration is readily removed by ordinary laundering without bleaches.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3d5fe6c4-d9c1-401d-886d-0382939ac2a4"></a><a name="section-13"></a><p></p>
<p class="First">MANUFACTURED BY</p>
<p>STIEFEL LABORATORIES, INC.</p>
<p>CORAL GABLES, FL 33134</p>
<p>DISTRIBUTED BY</p>
<p>PERRIGO®</p>
<p>ALLEGAN, MI 49010</p>
<p>Rev. 10/07</p>
<p>82174</p>
<p>: 5L500 RC J1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_6c3a5b8a-0446-443a-868a-09c83523d3ad"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel - 30 g Carton</h1>
<p class="First">Seb-Prev™ Cream</p>
<p>(Sodium Sulfacetamide 10%)</p>
<p>For Dermatologic Use Only.  Not for Ophthalmic Use.</p>
<p>Rx Only</p>
<div class="Figure">
<img alt="Seb-Prev(tm) Cream - 30 g Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=51e81749-8306-4e3e-9165-28c34cdcca62&amp;name=746e4edd-4c3e-443a-9775-d64d494f1850-02.jpg"><p class="MultiMediaCaption">Seb-Prev(tm) Cream - 30 g Carton</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_fb90555f-881a-4fac-b9e6-0e1ffde20473"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel - 30 g Tube</h1>
<p class="First">Seb-Prev™ Cream</p>
<p>(Sodium Sulfacetamide 10%)</p>
<p>For Dermatologic Use Only.  Not for Ophthalmic Use.</p>
<p>Rx Only</p>
<div class="Figure">
<img alt="Seb-Prev(tm) Cream - 30 g Tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=51e81749-8306-4e3e-9165-28c34cdcca62&amp;name=746e4edd-4c3e-443a-9775-d64d494f1850-03.jpg"><p class="MultiMediaCaption">Seb-Prev(tm) Cream - 30 g Tube</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_240dd9a1-edcb-47f4-8fca-36797a77c14f"></a><a name="section-16"></a><p></p>
<h1>Principal Display Panel - 60 g Carton</h1>
<p class="First">Seb-Prev™ Cream</p>
<p>(Sodium Sulfacetamide 10%)</p>
<p>For Dermatologic Use Only.  Not for Ophthalmic Use.</p>
<p>Rx Only</p>
<div class="Figure">
<img alt="Seb-Prev(tm) Cream - 60 g Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=51e81749-8306-4e3e-9165-28c34cdcca62&amp;name=746e4edd-4c3e-443a-9775-d64d494f1850-04.jpg"><p class="MultiMediaCaption">Seb-Prev(tm) Cream - 60 g Carton</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bc4913a1-66aa-414d-8ffe-1c7a3a3a74b1"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel - 60 g Tube</h1>
<p class="First">Seb-Prev™ Cream</p>
<p>(Sodium Sulfacetamide 10%)</p>
<p>For Dermatologic Use Only.  Not for Ophthalmic Use.</p>
<p>Rx Only</p>
<div class="Figure">
<img alt="Seb-Prev(tm) Cream - 60 g Tube" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=51e81749-8306-4e3e-9165-28c34cdcca62&amp;name=746e4edd-4c3e-443a-9775-d64d494f1850-05.jpg"><p class="MultiMediaCaption">Seb-Prev(tm) Cream - 60 g Tube</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PERRIGO SEB PREV 		
					</strong><br><span class="contentTableReg">sodium sulfacetamide cream</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:45802-954</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SULFACETAMIDE SODIUM</strong> (SULFACETAMIDE) </td>
<td class="formItem">SULFACETAMIDE SODIUM</td>
<td class="formItem">100 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:45802-954-94</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:45802-954-96</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">08/07/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Perrigo New York Inc
							(078846912)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>746e4edd-4c3e-443a-9775-d64d494f1850</div>
<div>Set id: 51e81749-8306-4e3e-9165-28c34cdcca62</div>
<div>Version: 3</div>
<div>Effective Time: 20100816</div>
</div>
</div> <div class="DistributorName">Perrigo New York Inc</div></p>
</body></html>
